top of page
Company Profile & History
Company Profile
Company name
Kamui Pharma, Inc.
Company establishment date
4/2, 2018
Business content
Pharmaceuticalization of bioactive substances derived from probiotics (effective microorganisms)
Board member
CEO
Naoki OGAWA（Associate Professor of Intellectual Property Center, Asahikawa Medical University）
CSO
Mikihiro FUJIYA（Proffessor of Division of Gastroenterology ,
Department of Internal Medicine, Asahikawa Medical University）
Director
Hiroyuki HASEGAWA（Operating Officer of Mitsubishi UFJ Capital Co., Ltd.）
Accounting adviser
Kenji MAEKAWA（Representative of MAEKAWA CPA Office）
History
2007
Drug discovery research of probiotic-derived bioactive substances in full swing
2010
Patent application filed for "long-chain polyphosphoric acid" as a treatment for IBD.
2016
Patent application filed for "Ferrichrome" as an anti-tumor agent.
2016.4
First in Human Clinical research on patients with relapsing ulcerative colitis
2018.4
Kamui Pharma, Inc. is established within Asahikawa Medical University.
2018.5
Series A Raised 225 million yen as a third party allocation
2022.7
Series B Raised 650 million yen as a third party allocation
bottom of page